FDA grants IDE approval for Renerva’s trial of nerve capping device
December 4, 2025
The trial will enroll patients who are undergoing nerve management procedures for severe neuropathic pain.
The trial will enroll patients who are undergoing nerve management procedures for severe neuropathic pain.
MED-EL’s cochlear implants are now FDA-approved in children seven months and older with bilateral sensorineural hearing loss (SNHL).
Partnership will expand Shoulder Innovations’ Disruptive Ecosystem with Advanced Enabling Technology, Complementing Surgeon and Patient Needs in the ASC
Three- and Four-Laser BD FACSDiscover A8 Cell Analysers Expand Accessibility of Spectral, Real-Time Imaging Cell Analysis
The approval is a major endorsement of Biomoneta’s scientific breakthrough and an important inflection point for Beyond Next Ventures India (BNV India)
Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities
Today, NeuroVice announced that PATI is now commercially available, marking a breakthrough moment for millions of patients living with focal and grand-mal seizures.
SURREY, BC, Dec. 4, 2025 /PRNewswire/ – mlHealth 360 today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (K250694) for Scaida BrainCT-ICH, an AI-powered triage solution designed to address critical bottlenecks in acute care radiology.
Fusion oncoproteins arise when a gene fuses with another gene and acquires new abilities. Such abilities can include the formation of biomolecular condensates, “droplets” of concentrated proteins, DNA or RNA.
MIDDLETON, Wis., Dec. 3, 2025 /PRNewswire/ — Natus Medical Incorporated announced the electrographic status epilepticus diagnosis capability of its BrainWatch point-of-care EEG solution, featuring integrated Persyst analysis software which has received 510(k) clearance from the U.S. Food and Drug Administration.